Angiopoietin-2 levels in glucose intolerance, hypertension, and metabolic syndrome in Asian Indians (Chennai Urban Rural Epidemiology Study-74)

Metabolism: Clinical and Experimental
Sathish AnuradhaMadhulika Dixit

Abstract

The aim of the study was to look at the association of angiopoietin-2 (Ang-2) in Asian Indian subjects with different grades of glucose intolerance and in those with hypertension and metabolic syndrome (MS). Three groups were recruited from the Chennai Urban Rural Epidemiology Study, a population-based study in southern India, as follows: group 1, normal glucose tolerance(n = 45); group 2, impaired glucose tolerance (IGT) (n = 45); and group 3, type 2 diabetes mellitus (T2DM) (n = 40). Angiopoietin-2 was estimated by enzyme-linked immunosorbent assay. Hypertension was diagnosed based on medical history, drug treatment of hypertension, and/or if the subjects had systolic blood pressure at least 130 mm Hg and/or diastolic blood pressure at least 85 mm Hg. Metabolic syndrome was defined using modified National Cholesterol Education Program-Adult Treatment Panel III guidelines. Subjects with T2DM had higher age-adjusted Ang-2 values (3741 +/- 1429 pg/mL) compared with subjects with IGT (1907 +/- 855 pg/mL) and normal glucose tolerance (1462 +/- 856 pg/mL) (P for trend < .001). Regression analysis showed that there was a linear increase in mean Ang-2 values with increasing severity of glucose intolerance, even after adjusting for ag...Continue Reading

References

Feb 7, 2001·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·T KorffH G Augustin
May 23, 2001·JAMA : the Journal of the American Medical Association·UNKNOWN Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
Oct 9, 2002·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Tamami OkamotoZenji Makita
Dec 31, 2002·Investigative Ophthalmology & Visual Science·Hitoshi TakagiYoshihito Honda
Jul 23, 2003·Current Pharmaceutical Design·F N KieferE J Battegay
Mar 12, 2004·Journal of the American College of Cardiology·Aun Yeong ChongGregory Y H Lip
May 4, 2004·Annals of Medicine·Gregory Y H Lip, Andrew D Blann

❮ Previous
Next ❯

Citations

Jul 24, 2012·Endocrine·Sazan RasulAlexandra Kautzky-Willer
Jun 28, 2011·Cardiovascular Diabetology·Sazan RasulAlexandra Kautzky-Willer
Jan 26, 2016·Metabolic Syndrome and Related Disorders·Harry Robberecht, Nina Hermans
Aug 1, 2013·European Journal of Heart Failure·Roberto LorbeerWolfgang Lieb
Oct 26, 2016·Current Diabetes Reports·Peter A Campochiaro, Kevin G Peters
Nov 1, 2015·Circulation·Hertzel C GersteinUNKNOWN Outcome Reduction With Initial Glargine Intervention Trial Investigators
Nov 19, 2021·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Chang ChuBerthold Hocher

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.